Remo Panaccione

Active 1999–2026

278
Papers
56,643
Citations
108
h-index
258
i10-index

Citations

Citations per year for Remo Panaccione1991: 1 citations1993: 3 citations1995: 1 citations1999: 1 citations2000: 1 citations2001: 6 citations2002: 22 citations2003: 23 citations2004: 29 citations2005: 22 citations2006: 36 citations2007: 85 citations2008: 103 citations2009: 131 citations2010: 190 citations2011: 229 citations2012: 218 citations2013: 387 citations2014: 424 citations2015: 490 citations2016: 487 citations2017: 563 citations2018: 598 citations2019: 2,171 citations2020: 2,467 citations2021: 2,271 citations2022: 2,007 citations2023: 2,005 citations2024: 3,178 citations2025: 1,730 citations2026: 44 citations1992: no citations, so this year is not shown1994: no citations, so this year is not shown1996–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,867 citing papers, 18.2% of this breakdownChina: 2,489 citing papers, 11.7% of this breakdownUnited Kingdom: 1,504 citing papers, 7.1% of this breakdownCanada: 1,428 citing papers, 6.7% of this breakdownItaly: 1,221 citing papers, 5.7% of this breakdownFrance: 977 citing papers, 4.6% of this breakdownGermany: 945 citing papers, 4.4% of this breakdownNetherlands: 720 citing papers, 3.4% of this breakdownSpain: 656 citing papers, 3.1% of this breakdownBelgium: 579 citing papers, 2.7% of this breakdownJapan: 547 citing papers, 2.6% of this breakdownAustralia: 519 citing papers, 2.4% of this breakdown
0%18.2%Other 27.4%

Fields

  • Biochemistry, Genetics and Molecular Biology61%
  • Medicine23.9%
  • Immunology and Microbiology7.1%
  • Neuroscience1.5%
  • Nursing1.4%
  • Agricultural and Biological Sciences1.3%
  • Other3.8%

Topics

  • Inflammatory Bowel Disease20%
  • Gut microbiota and health6.6%
  • Microscopic Colitis6.6%
  • Rheumatoid Arthritis Research and Therapies3.2%
  • Autoimmune and Inflammatory Disorders2.6%
  • Clostridium difficile and Clostridium perfringens research1.9%
  • Other59.1%

Coauthors

All papers

Open in search
  1. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies

    Authors: , , , , , , , , , , , - The Lancet 2017 cited by 5,927

  2. Crohn’s disease

    Authors: , , , , , , , , - Nature Reviews Disease Primers 2020 cited by 1,008

  3. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

    Authors: , , , , , , , , , , - Gastroenterology 2011 cited by 4,818

  4. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

    Authors: , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 1,180

  5. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2022 cited by 597

  6. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

    Authors: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 427

  7. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marc Ferrante - The Lancet 2022 cited by 387

  8. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Silvio Danese, Julián Panés, Guillaume Bouguen, Sarah O’Donnell, Benjamin Pariente, Shawn Winer, Stephen B. Hanauer, J -F Colombel - The American Journal of Gastroenterology 2015 cited by 1,838

  9. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2017 cited by 912

  10. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Geert D’Haens - The Lancet 2022 cited by 316

  11. Gut Microbiome Composition Is Associated With Future Onset of Crohn’s Disease in Healthy First-Degree Relatives

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Baruch Yerushalmi, Andrew D. Paterson, Wei Xu, Maria Abreu, Paul L. Beck, Çharles N. Bernstein, Kenneth Croitoru, Levinus A. Dieleman, Brian G. Feagan, Anne M. Griffiths, David S. Guttman, Kevan Jacobson, Gilaad G. Kaplan, Denis O. Krause, Karen Madsen, John K. Marshall, Paul Moayyedi, Mark J. Ropeleski, Ernest G. Seidman, Mark S. Silverberg, Scott B. Snapper, Andy Stadnyk, Hillary Steinhart, Michael G. Surette, Dan Turner, Tom Walters, Bruce A. Vallance, Guy Aumais, Alain Bitton, Maria Cino, Jeff Critch, Lee A. Denson, C Deslandres, Wael El-Matary, Hans Herfarth, Peter Higgins, Hien Q. Huynh, Jeffrey S. Hyams, David Mack, Jerry McGrath, Anthony Otley, Remo Panancionne, Kenneth Croitoru - Gastroenterology 2023 cited by 192

  12. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Clint Behrend, Geert Bezemer, Guillaume Bonnaud, Marija Branković, Ik Jang Byung, Xavier Calvet, Karen A. Chachu, Júlio Maria Fonseca Chebli, Jae Hee Cheon, Halina Cichoż‐Lach, Larry Clark, Fraser Cummings, Kunal Dalal, Silvio Danese, Nanne K.H. de Boer, Maria de Lourdes Abreu Ferrari, Étienne Désilets, Predrag Dugalić, George Duvall, Olga Fedorishina, Rafał Filip, Cristina Flores, Ronald Fogel, James Fon, Michael Frankel, Keith Friedenberg, Walter Fries, Vassileva Galina, Piotr Gietka, Rishi Goel, Peter Hasselblatt, Hans Herfarth, László Herszényi, Pieter Hindryckx, Frank Hoentjen, Carmen Horjus Talabur Horje, Satish Iduru, Peter M. Irving, Robert J. Isfort, Vipul Jairath, Michael Jones, Dilara Kalimullina, Jeffry Katz, Manreet Kaur, Sunil K Khurana, Joo Sung Kim, Young‐Ho Kim, D Kleczkowski, Slavko Knezevic, Aaron Knoll, Louis Y Korman, Iskren Kotzev, Andrey Kulyapin, Kang‐Moon Lee, Desirée Leemreis, Jarosław Leszczyszyn, Jimmy K. Limdi, Jack J. Lissauer, Edward V. Loftus, Ewa Małecka‐Panas, John K. Marshall, Emese Mihály, Lukáš Milan, Giovanni Monteleone, Aleksandar Nagorni, Danuta Owczarek, Nichole Palekar, Remo Panaccione, Young Soo Park, Sang Hyoung Park and 43 more - The Lancet 2022 cited by 297

  13. Global Hospitalization Trends for Crohn’s Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yang Sun, Ida Hilmi, Raja Affendi Raja Ali, Mukesh S Paudel, Mansour Altuwaijri, Juanda Leo Hartono, Shu Chen Wei, Julajak Limsrivilai, Sara El Ouali, Beatriz Iade Vergara, Viet Hang Dao, Paul Kelly, Phoebe Hodges, Yinglei Miao, Maojuan Li - Clinical Gastroenterology and Hepatology 2022 cited by 272

  14. Altered Gut Microbiome Composition and Function Are Associated With Gut Barrier Dysfunction in Healthy Relatives of Patients With Crohn’s Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2022 cited by 194

  15. Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2019 cited by 432

  16. Increased Intestinal Permeability Is Associated With Later Development of Crohn’s Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gilaad G. Kaplan, Denis O. Krause, Karen Madsen, John Marshall, Paul Moayyedi, Mark J. Ropeleski, Ernest G. Seidman, Mark S. Silverberg, Scott B. Snapper, Andy Stadnyk, Hillary Steinhart, Michael G. Surette, Dan Turner, Thomas D. Walters, Bruce A. Vallance, Guy Aumais, Alain Bitton, Maria Cino, Jeff Critch, Lee A. Denson, Colette Deslandres, Wael El‐Matary, Hans Herfarth, Peter Higgins, Hien Q. Huynh, Jeff Hyams, David Mack, Jerry McGrath, Anthony Otley, Remo Panancionne, Guy Aumais, Robert N. Baldassano, Çharles N. Bernstein, Maria Cino, Lee A. Denson, Colette Deslandres, Wael El‐Matary, Anne M. Griffiths, Charlotte Hedin, Hans Herfarth, Peter Higgins, Séamus Hussey, Hien Hyams, Kevan Jacobson, David J. Keljo, David Kevans, Charlie W. Lees, David Mack, John Marshall, Jerry McGrath, Sanjay K. Murthy, Anthony Otley, Remo Panaccione, Nimisha Parekh, Sophie Plamondon, Graham Radford-Smith, Mark J. Ropeleski, Joel R. Rosh, David T. Rubin, Michael Schultz, Ernest G. Seidman, Corey A. Siegel, Scott B. Snapper, Hillary Steinhart, Dan Turner, Kenneth Croitoru - Gastroenterology 2020 cited by 310

  17. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis

    Authors: , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2021 cited by 294

  18. Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2023 cited by 120

  19. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

    Authors: , , , , , , , , , , - Gastroenterology 2006 cited by 2,250

  20. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

    Authors: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2012 cited by 1,128

  21. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

    Authors: , , , , , , , , , , , , , , , , , , , - Gastroenterology 2022 cited by 198

  22. PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Gut 2022 cited by 137

  23. Invasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with IBD status of the host

    Authors: , , , , , , , - Inflammatory Bowel Diseases 2011 cited by 586

  24. Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

    Authors: , , , , , , , , , , - Gastroenterology 2013 cited by 961